| |
 
| |
 |
| |
|
|
| |
Profile |
|
| |
|
|
| |
is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including metabolic disease, oncology, CNS, inflammation and cardiovascular disease.
Plexxikon's unique discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and creative partnering, have been key drivers of the company's success since it began operations in 2001.
With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. This systematic, cost-efficient approach allows Plexxikon to leverage its chemistry investment in any one drug target for other targets within that family. This strategy has resulted in a comprehensive portfolio and pipeline of opportunities for both its internal and partnered programs.
 Product Pipeline pdf
Corporate Fact Sheet |
|
| |
|
|
|
|
 |
|
|
| |
| |
|
| |
|
|
| |
Profile |
|
| |
|
|
| |
is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including
cardio-renal disease, CNS, inflammation, metabolic disease
and oncology.
Plexxikon's unique discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and creative partnering, have been key drivers of the company's success since it began operations in 2001.
With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process
in conjunction with a highly specialized scaffold-like
screening library, to design new drug candidates within various families of drug targets. This systematic, cost-efficient approach allows Plexxikon to leverage its target-specific chemistry investment for
multiple targets within a given family.
Plexxikon’s business strategy is to generate competitively differentiated drug candidates across multiple therapeutic areas, then partner at the IND or early clinical stage for further co-development and commercialization. This has resulted in a comprehensive portfolio and pipeline of opportunities, generating significant value for Plexxikon, its collaborators and investors.
Product Pipeline
Corporate Fact Sheet |
|
| |
|
|
|
|
|
| |
| | | | | | |
| | | | | | | | |
| © 2007 Plexxikon Inc. | Site design by |
| |
|
|